The British pharmaceutical company GSK is investing almost 100 million euros in its location in Rixensart, Walloon Brabant, where a “laboratory of the future” is being built.
GSK has invested billions in our country over the past few years. The pharmaceutical company not only has the world’s largest vaccine factory in Wavre, but is also the group’s largest research and development center in Rixensart. Many of the vaccines that GSK markets are developed and manufactured in Walloon Brabant.
The company will now invest a further almost 100 million euros in Rixensart, in a “laboratory of the future”. All clinical laboratory activities are combined in one building, including an automated system for managing all clinical samples from around the world.
The investment consolidates Rixensart’s position as the world’s largest research and development center for vaccines and strengthens Belgium’s strategic role in the vaccine industry.
GSK also announced on Tuesday that Belgian Jamila Louahed, already Vice President and Head of Global Research and Development at GSK, will head the Rixensart site from January.
Incidentally, the investment is separate from GSK’s activities for a corona vaccine. GSK is working with Sanofi to develop a vaccine. On Friday, both companies reported a delay in the program after disappointing results in elderly patients. The goal now is the fourth quarter of next year.